Checked.be
Active
BE 0423.155.372Public limited company
HANDI-MOVE
Ten Beukeboom(App) 13 ·9400 Ninove, Belgium· 43 yrs active
Sector: Manufacture of medical and dental instruments and supplies
(32500)
Conclusion
HANDI-MOVE has been active since 1982 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €13.94M and a net result of €1.89M. Equity is growing by ~10% per year across the filed fiscal years. Its solvency ranks better than 93% of 75 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Based on the State Gazette, CBE and 3 annual accounts.
Key figures
| Equity | €13.94M |
| Net result | €1.89M |
| Staff (FTE) | 29 |
| Better than sector | 93% |
Financial profile
88
/ 100
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Health
93
Profitability
68
Solvency
100
Growth
78
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
Long-established
Founded in 1982, 43 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
93
/ 100
Excellent
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€1.30M
estimate, not credit advice
Score history
93
2023
100
2024
93
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 6.45 (≥ 1.5)
+10
Quick ratio
Quick ratio 4.98 (≥ 1.0)
+5
Leverage
Debt/equity 0.16 (< 1.0)
+10
Profitability
ROE 14% (≥ 10%)
+10
Interest coverage
Interest coverage 7.8× (≥ 3×)
+8
Profit trend
Net profit down YoY
-3
Equity growth
Equity growing YoY
+3
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 17-07-2026 with the NBB · fiscal year 2025 · full schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing
Equity: growth of ~10%/year over 3 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 32, Other manufacturing · compared across all schema types (micro, abbreviated and full combined)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 86.0% | 33.0% | |
| Net result | €1.89M | €11k | |
| Equity | €13.94M | €38k | |
| Gross operating margin | €5.25M | €35k | |
| Total assets | €16.22M | €195k |
€2.98M
-16.2%
23-25
€1.89M
-26.0%
23-25
€2.21M
-21.1%
23-25
€16.22M
+5.7%
23-25
€13.94M
+10.2%
23-25
€11.34M
+11.5%
23-25
29
+5.8%
23-25
€2.23M
+7.0%
23-25
€526k
-30.6%
23-25
€570k
-55.6%
23-25
€2.24M
-15.4%
23-25
€2.08M
-11.7%
23-25
€133k
-49.6%
23-25
6.45
+21.3%
23-25
4.98
+19.9%
23-25
86.0%
+4.2%
23-25
0.16
-23.2%
23-25
13.5%
-32.8%
23-25
11.6%
-30.0%
23-25
7.82
-56.6%
23-25
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Deposit | full schema | abbreviated schema | abbreviated schema |
| Revenue | - | - | - |
| EBITDA | €2.98M | €3.55M | €2.41M |
| Net profit | €1.89M | €2.55M | €1.55M |
| Cash flow | €2.21M | €2.80M | €1.80M |
| Staff costs | €2.23M | €2.09M | €2.07M |
| Income taxes | €526k | €757k | €431k |
| Dividends | €570k | €1.28M | - |
| Total assets | €16.22M | €15.34M | €13.11M |
| Equity | €13.94M | €12.66M | €11.42M |
| Debt | €2.24M | €2.65M | €1.63M |
| of which ≤ 1y | €2.08M | €2.36M | €1.31M |
| of which > 1y | €133k | €265k | €196k |
| Working capital | €11.34M | €10.18M | €9.99M |
| Employees (FTE) | 29.0 | 27.4 | 29.1 |
Note: these years are not on the same basis. The filed schemas differ (full schema, abbreviated schema), so the columns are not directly comparable.
Ratios (computed)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Current ratio | 6.45 | 5.31 | 8.64 |
| Quick ratio | 4.98 | 4.15 | 6.53 |
| Working capital ratio | 69.9% | 66.3% | 76.2% |
| Solvency | 86.0% | 82.5% | 87.1% |
| Debt / equity | 0.16 | 0.21 | 0.14 |
| Long-term debt ratio | 0.01 | 0.02 | 0.02 |
| Interest coverage | 7.82 | 18.02 | 9.20 |
| Gross margin | - | - | - |
| Net margin | - | - | - |
| ROA | 11.6% | 16.6% | 11.9% |
| ROE | 13.5% | 20.1% | 13.6% |
| EBITDA margin | - | - | - |
| Days sales outstanding | - | - | - |
| Days payable outstanding | - | - | - |
| Inventory turnover | - | - | - |
| Days inventory (DSI) | - | - | - |
Balance-sheet composition 2025
Full annual accounts (27 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Balance sheet, Assets | ||||
| TOTAL ASSETS | 20/58 | €16.22M | €15.34M | €13.11M |
| Fixed assets | 21/28 | €2.79M | €2.81M | €1.82M |
| Intangible fixed assets | 21 | €57k | €77k | €15k |
| Tangible fixed assets | 22/27 | €2.72M | €2.71M | €1.78M |
| Financial fixed assets | 28 | €17k | €17k | €17k |
| Current assets | 29/58 | €13.43M | €12.54M | €11.30M |
| Stocks & contracts in progress | 3 | €3.06M | €2.74M | €2.76M |
| Amounts receivable within one year | 40/41 | €3.10M | €3.23M | €2.23M |
| Investments | 50/53 | - | €2.02M | €1.02M |
| Cash & bank | 54/58 | €6.53M | €3.86M | €4.61M |
| Balance sheet, Equity & liabilities | ||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €16.22M | €15.34M | €13.11M |
| Equity | 10/15 | €13.94M | €12.66M | €11.42M |
| Contributions / capital | 10/11 | €125k | €125k | €125k |
| Reserves | 13 | €13.44M | €12.16M | €10.92M |
| Provisions & deferred taxes | 16 | €31k | €32k | €58k |
| Amounts payable | 17/49 | €2.24M | €2.65M | €1.63M |
| Amounts payable after one year | 17 | €133k | €265k | €196k |
| Amounts payable within one year | 42/48 | €2.08M | €2.36M | €1.31M |
| Trade debts payable within one year | 44 | €558k | €1.17M | €453k |
| Income statement | ||||
| Gross operating margin | 9900 | €5.25M | €5.58M | €4.46M |
| Operating result | 9901 | €2.65M | €3.30M | €2.16M |
| Financial income | 75 | €140k | €205k | €90k |
| Financial charges | 65 | €381k | €197k | €262k |
| Result before taxes | 9903 | €2.41M | €3.31M | €1.99M |
| Income taxes | 67/77 | €526k | €757k | €431k |
| Net result for the period | 9904 | €1.89M | €2.55M | €1.55M |
| Result to be appropriated | 9905 | €2.16M | €2.55M | €923k |
Legal Structure
| NACE primary | Manufacture of medical and dental instruments and supplies(32500) |
| Legal form | Public limited company(014) |
| Incorporation | 28-10-1982 |
| Status | Active |
| Postal code | 9400 |
Establishment units
Camfida
since 19822.021.290.948
Benfida
since 20202.309.823.881
Real-estate footprint
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 41003A0306/00B000 | Flanders | 9,125 m² | 1 · 5,715 m² | 8.2 m · 2 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2026
17-07
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
18-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Highest result since 2023net €2.55M ▲64%
Operating result €3.30M, net result €2.55M, both a record.
18-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
20-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
20-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
31-08
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 31 days late
2020
20-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
28-08
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema · 28 days late
2018
20-07
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
20-07
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 5 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Manufacture of medical and dental instruments and supplies3250033101Wholesale of pharmaceutical and medical goods46460Manufacture of machinery and equipment not elsewhere classified28220
Names & trade names
| Legal nameNL | HANDI-MOVE |
Similar companies
MOLNLYCKE HEALTH CARE
BE 0462.556.475 · Waremme
ANALIS
BE 0430.744.435 · Namur
ORTHO - CLINICAL DIAGNOSTICS
BE 0419.897.954 · Zaventem
VIGO
BE 0444.471.717 · Wetteren
Medline International Belgium
BE 0462.010.802 · Machelen (Brab.)